What Cilafil Treats: Main Uses and Benefits

Cilafil (Sildenafil) is commonly used to help with managing symptoms across distinct clinical domains, focusing on supporting local circulation and assisting with functional ability. The medication is applied across areas where symptomatic support for vascular function is needed.

Supporting Functional Health

The primary therapeutic domains where the medication is relevant include the management of Erectile Dysfunction (ED) and the chronic treatment of Pulmonary Arterial Hypertension (PAH). It is also considered relevant for managing symptoms linked to local tissue distress, such as those that become disruptive during severe episodes of cold-induced vascular constriction. Cilafil is generally used in situations involving certain distressing symptoms, where it helps address symptom clusters that may become intense or disruptive. For adult men with ED, using Cilafil provides support that helps ease the overall symptom burden of functional strain, and may assist with supporting stability for sexual health. For PAH patients, this supportive therapeutic benefit contributes to improved day-to-day comfort during symptomatic periods, and may assist with managing symptoms that interfere with daily functioning.

Quick Fact: Relief for Functional Strain
Primary Focus: Symptomatic relief for functional deficits stemming from poor localized blood flow.
Core Benefit: Provides support that helps ease the overall burden of symptoms related to sexual health and pulmonary vascular resistance.

Regulatory References

1. MedlinePlus Drug Information

Who Can and Cannot Use Cilafil?

This section defines patient eligibility for Cilafil (Sildenafil) based solely on official regulatory classifications, such as contraindications and usage restrictions.

---

Absolute Prohibitions (Contraindications)

Cilafil must not be used by patients who have a known hypersensitivity to Sildenafil or any component of the tablet. Use is strictly contraindicated in patients who are concurrently taking any form of nitrates (e.g., nitroglycerin) or nitric oxide donors, as well as those using soluble guanylate cyclase (sGC) stimulators (e.g., riociguat). Additionally, the medicine is prohibited for patients with severe hepatic impairment (Child-Pugh Class C), recent stroke or myocardial infarction, severe hypotension (blood pressure < 90/50 mmHg), or a history of Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION) or hereditary degenerative retinal disorders.

---

Age and Condition-Based Restrictions

Category	Official Eligibility Status	Applicable Indication
Pediatric Use	Not recommended for children and adolescents under 18 years for the ED indication. Allowed for Pulmonary Arterial Hypertension (PAH) in patients aged 1 to 17 years.	ED, PAH
Severe Organ Impairment	Severe hepatic impairment is prohibited. Use in severe renal impairment requires special prescribing consideration.	General
Pregnancy and Lactation	Not established (insufficient data to determine risk to the infant or fetus); not indicated for use in women for the ED condition.	PAH, General
Conditional Use	Caution is required for patients with anatomical deformation of the penis, conditions predisposing to priapism (e.g., sickle cell disease), and those on alpha-blocker therapy.

Cilafil Interactions with other medicines and products

Official regulatory documents define the interaction profile of Cilafil (tadalafil) based on two primary mechanisms: pharmacodynamic potentiation of blood pressure lowering and pharmacokinetic changes through enzyme metabolism.

Interaction Domain	Practical Regulatory Implication
Organic Nitrates (e.g., nitroglycerin, isosorbide)	Contraindicated. Co-administration may potentiate the hypotensive effect, leading to a severe and potentially dangerous drop in blood pressure.
Guanylate Cyclase (GC) Stimulators (e.g., riociguat)	Contraindicated. Concomitant use with GC stimulators is prohibited due to the risk of symptomatic hypotension.
Potent CYP3A4 Inhibitors (e.g., ritonavir, ketoconazole)	Dose Adjustment Required. These medicines increase Cilafil exposure. The recommended maximum dose must be reduced for on-demand use (limit to 10 mg no more than once every 72 hours) and once-daily use (limit to 2.5 mg).
Alpha-Blockers and Other Antihypertensives	Use with Caution/Monitoring. Cilafil has vasodilatory properties that may potentiate the blood pressure-lowering effects of these agents. Patients must be stable on alpha-blocker therapy before starting Cilafil at the lowest recommended dose.
CYP3A4 Inducers (e.g., rifampicin)	Decreased Efficacy. These products decrease Cilafil exposure, which may reduce its effectiveness.

Co-administration with other PDE5 inhibitors or other erectile dysfunction treatments is not recommended as safety and efficacy have not been studied. Patients are advised that substantial alcohol consumption (e.g., ge 5 units) may increase the potential for orthostatic signs and symptoms due to combined vasodilatory effects. Specific maximum dose limitations apply to patients with renal or hepatic impairment when co-administered with CYP3A4 inhibitors.

Enzyme Regulation and Selective Target Inhibition

Cilafil's mechanism is centered on the selective competitive inhibition of the enzyme Phosphodiesterase type 5 (PDE5), which is prevalent in specific vascular smooth muscle cells. By blocking PDE5, the drug prevents the hydrolysis (breakdown) of the signaling molecule cyclic Guanosine Monophosphate (cGMP), thereby sustaining the presence of the signaling molecule cGMP, a key mediator of smooth muscle relaxation.

---

Signal Potentiation and Vascular Tone Modulation

The primary action is to enhance the function of the body’s natural Nitric Oxide (NO) / cGMP signaling cascade. This sustained increase in cGMP levels within the smooth muscle cells causes downstream physiological effects, specifically leading to relaxation of the vascular smooth muscle and a resulting vasodilation. This physiological change results in increased localized tissue perfusion and a decrease in vascular resistance.

---

Mechanistic Constraints

The drug is strictly dependent on the endogenous release of Nitric Oxide to initiate the cGMP production cascade, indicating that the drug sustains an existing signal rather than creating a novel one. This constraint means the mechanism is dependent on the level of endogenous NO release; its physiological effect is proportional to, and constrained by, the initial cGMP production.

Cilafil (Sildenafil) is administered under two distinct, official protocols depending on the condition. The medication is available as oral tablets or oral suspension, with an intravenous (IV) bolus form approved for patients with pulmonary arterial hypertension (PAH) who are temporarily unable to tolerate oral intake.

For as-needed use, the recommended starting oral dose is 50 mg, which is typically taken about one hour before the activity. Based on individual factors, the dose may be adjusted to a minimum of 25 mg or increased to a maximum single dose of 100 mg, with a strict limit of once per day. The tablet can be taken with or without food, but ingestion with a high-fat meal can delay the onset of the medicine's action.

For chronic PAH therapy, the standard regimen is 20 mg oral, administered three times a day (TID), with doses separated by four to six hours. This chronic regimen may be titrated up to a maximum of 80 mg TID. Special dosing rules apply to certain populations; for the as-needed regimen, a 25 mg starting dose should be considered for older adults (65 years) and those with severe hepatic or renal impairment. The oral suspension requires reconstitution with a specific amount of water prior to initial use and must be accurately measured with a calibrated oral device.

Cilafil is a phosphodiesterase type 5 (PDE5) inhibitor, a class of medication used to treat conditions such as erectile dysfunction (ED) and the signs and symptoms of benign prostatic hyperplasia (BPH). Clinical evidence from multiple Phase 3 trials and integrated analyses has confirmed its efficacy and favorable safety profile across various patient populations.

---

Efficacy in Erectile Dysfunction

Clinical trials have demonstrated that Cilafil significantly improves erectile function in men with ED of various severities and etiologies (causes). The medication is available for two primary dosing strategies: on-demand (taken before anticipated sexual activity) and once-daily (a lower dose taken daily).

• On-Demand Dosing: Studies show a high success rate for intercourse attempts, with many patients achieving an erection firm enough for successful completion of sexual activity. Its long half-life, up to 36 hours, provides an extended window of therapeutic opportunity, allowing for greater spontaneity than other PDE5 inhibitors.
• Once-Daily Dosing: This regimen is suitable for men who anticipate frequent sexual activity (at least twice weekly). Meta-analyses indicate that long-term, once-daily use is effective and well-tolerated, leading to significant improvement in the International Index of Erectile Function–Erectile Function domain scores compared to placebo.

---

Safety and Tolerability

The safety profile of Cilafil is generally consistent with the PDE5 inhibitor class. In clinical trials, the most commonly reported adverse events (occurring in 2% or more of patients on the once-daily 2.5 mg and 5 mg doses) were typically mild to moderate. Discontinuations due to adverse events were infrequent.

System Organ Class	Common Adverse Event	Incidence (%)
Gastrointestinal disorders	Dyspepsia	3.9
Infections and infestations	Nasopharyngitis	3.4
Musculoskeletal disorders	Back pain, Myalgia	2.9, 2.3

The long-term safety of Cilafil has been established, with no new safety concerns identified in extended real-world surveillance studies, including those involving elderly patients (aged 75 and over). The drug is primarily metabolized by the liver, requiring careful consideration of dosage in patients with pre-existing hepatic or renal impairment.

Common questions about Cilafil (FAQ)

---

Q: How quickly does Cilafil start to work after taking it?

A: According to the official product information for its as-needed use, this medicine can be taken anywhere from 30 minutes to 4 hours before activity. Patients commonly take it about one hour beforehand. The amount of time it takes to start working can be affected by individual factors and whether the drug is taken with a high-fat meal.

Q: What are the most common reported side effects of Cilafil?

A: The most common adverse reactions reported in clinical trials include headache, dyspepsia (indigestion), flushing (reddening of the face and neck), and epistaxis (nosebleeds). Regulatory documents classify these as the effects most frequently reported by patients taking the medication.

Q: Are there any long-term health concerns associated with using Cilafil?

A: Long-term safety studies and regulatory reviews have been conducted for this medication. These reviews confirm a safety profile consistent with the medication class and generally have not identified new safety concerns over extended periods of use. Patients typically remain under the supervision of a healthcare provider for any long-term treatment.

Q: Do older adults react differently to Cilafil compared to younger patients?

A: Yes, official guidance states that a lower initial dose is a consideration for prescribing clinicians for older adults, defined as those 65 years and older, for on-demand use. This reduced starting dose is considered due to potential differences in how the body processes the medicine compared to younger patients.

Q: Does Cilafil lose its effectiveness over time?

A: Official information does not indicate that this medicine causes a loss of effectiveness or tolerance (known as tachyphylaxis) with continued chronic use. Changes in effectiveness are typically addressed with the prescribing healthcare provider.

Q: What should be done if an allergic reaction is suspected after taking Cilafil?

A: Official patient information states that immediate medical attention is necessary if a serious allergic reaction or specific severe symptoms, such as sudden hearing or vision loss, are experienced. These specific events are classified in regulatory documents as serious adverse reactions that warrant prompt medical review.

Q: What is the purpose of the inactive ingredients listed in Cilafil tablets?

A: The inactive ingredients are necessary components, or excipients, required for the tablet’s physical structure, stability, and proper absorption into the body. They are included to ensure the active drug is delivered effectively and safely.

Q: Can Cilafil be crushed, split, or chewed?

A: The medication is supplied as film-coated tablets, and the film-coated tablet dosage form is intended for use as supplied and should not be altered unless specifically instructed by a healthcare professional. Official instructions specify use of the intact tablet or the approved liquid form.

Q: Is there a patient information leaflet (PIL) available for Cilafil online?

A: Yes, patient information leaflets (PILs) or FDA-required Patient Information documents containing detailed prescribing and usage facts are made available online. These documents are typically published by government health authorities or through the drug's manufacturer.

Q: Is Cilafil available as a generic drug?

A: Yes, the active ingredient in Cilafil, Sildenafil, is widely available as a generic drug. The generic version contains the same active ingredient as the branded medication.

Q: What is the maximum time window for Cilafil to be effective?

A: For on-demand use, regulatory prescribing information indicates that the medicine may be taken up to 4 hours before anticipated activity. The drug is considered effective throughout this extended window of time.

Q: Is it common for Cilafil to be used alongside other treatments for the same condition?

A: Co-administration with other PDE5 inhibitors or other treatments for the same conditions, such as erectile dysfunction, is generally not supported by regulatory guidance because the safety and efficacy of these combinations have not been formally studied.

Q: Why do I hear about different strengths of Cilafil being prescribed?

A: Different strengths are prescribed because the medication has distinct official approvals for two different treatment regimens. A range of doses is approved for 'as-needed' use, and a separate, lower fixed-dose regimen is approved for the chronic management of pulmonary arterial hypertension (PAH).

Q: What evidence exists regarding Cilafil use in patients with diabetes?

A: Clinical trials for this medication have included patients with various underlying conditions, including diabetes mellitus. Official efficacy and safety data were assessed across these different patient groups.

Q: Is Cilafil known to affect blood pressure?

A: Yes, Cilafil possesses systemic vasodilatory properties, meaning it widens blood vessels. In healthy patients, this generally results in a mild and temporary decrease in blood pressure, as stated in the clinical pharmacology sections of official labels.

Q: Does alcohol consumption change how Cilafil works?

A: Official information advises that substantial alcohol consumption may increase the potential for symptoms of orthostatic hypotension, such as dizziness or lightheadedness when standing up. This is due to the combined blood pressure-lowering effects of the drug and alcohol.

Q: Is it normal to feel a headache after taking Cilafil?

A: Yes, headache is classified in regulatory documents as a very common adverse reaction. This means it is among the side effects reported most frequently in the drug’s clinical studies.

Q: Are there any known interactions between Cilafil and herbal supplements?

A: Official regulatory documents do not list every specific herbal supplement. However, caution is advised, particularly with supplements known to affect the CYP3A4 enzyme system in the liver, as these could potentially change the amount of the drug absorbed by the body.

Q: What is the difference between taking Cilafil as needed versus daily?

A: The official 'as-needed' dose is intended to provide a therapeutic window of effectiveness for spontaneous activity. The 'once-daily' dose, in contrast, aims to maintain a more constant level of the medicine in the system for men who anticipate frequent activity.

Q: What is the expected length of time Cilafil stays in the system?

A: Based on the pharmacological profile of the medicine, specifically its elimination half-life, the drug is expected to be largely cleared from the body within about one day after the last dose. This time frame is related to how the body naturally processes and eliminates the medication.

Q: Does taking Cilafil with food change its absorption?

A: Official instructions for on-demand use state that taking the medication with a high-fat meal can delay the time it takes for the medicine to start working. Otherwise, it may be taken with or without food.

Q: Is Cilafil a habit-forming drug?

A: There is no scientific evidence or regulatory guidance to suggest that this medication is physically addictive or habit-forming. It is not classified as a controlled substance by major regulatory bodies.

Q: Can Cilafil affect fertility in men or women?

A: Official data regarding the impact of the medication on fertility (the ability to conceive) are often cited as insufficient to make a determination. The drug is generally not indicated for use in women of reproductive potential for the erectile dysfunction condition.

Q: Are there different treatment goals associated with Cilafil use?

A: Yes, the treatment goals differ based on the condition being addressed. For pulmonary arterial hypertension (PAH), the goal is to improve exercise capacity, while for erectile dysfunction (ED), the goal is to improve erectile function for successful sexual activity.

Cilafil (Sildenafil) must be stored under specific conditions to maintain its quality and ensure safety, as directed by official regulatory labeling.

Official Storage and Handling Requirements

The tablets must be stored at Controlled Room Temperature, which is officially defined as 25 C (77 F), with permissible excursions between 15 C and 30 C (59 F and 86 F). To protect the medication from moisture, it must be kept in its original container and the container should remain tightly closed.

Safety and Disposal

For safety, all tablets must be strictly kept out of the sight and reach of children.

Disposal of any unused or expired product must be done according to local regulatory requirements. Sildenafil is not on the FDA's flush list and should not be thrown into household wastewater or drains.